Tranexamic acid

• CAS Number:

  1197-18-8

• UNSPSC Description:

  Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis [1][2][3][4][5].

• Target Antigen:

  AMPK; IGF-1R; Mitophagy; MMP

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Epigenetics;Metabolic Enzyme/Protease;PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Tranexamic-acid.html

• Purity:

  98.0

• Solubility:

  DMSO : < 1 mg/mL|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1CC[C@H](CN)CC1)O

• Molecular Weight:

  157.21

• References & Citations:

  [1]Prudovsky I, et al. Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation [J]. Journal of cellular physiology, 2019, 234(11): 19121-19129.|[2]Wu G, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator [J]. Blood advances, 2019, 3(5): 729-733.|[3]Draxler D F, et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis [J]. Journal of Thrombosis and Haemostasis, 2019, 17(12): 2174-2187.|[4]Hiramoto K, et al. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness [J]. Biomedicine & Pharmacotherapy, 2016, 80: 16-22.|[5]Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery [J]. New England Journal of Medicine, 1989, 320(13): 840-843.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched